MannKind Corp.’s share price more than doubled this morning, a day after its inhaled diabetes treatment was backed by an FDA advisory panel, Bloomberg BusinessWeek reports. Shares at midday fell back slightly to $7.10, a 77 percent gain.
11150 Santa Monica Boulevard, Suite 350
Los Angeles, CA 90025
323-549-5225
© Los Angeles Business Journal